and Human Services (HHS)
EXPIRED
NANOMEDICINE CENTER CONCEPT DEVELOPMENT AWARDS
RELEASE DATE: May 4, 2004
RFA Number: RFA-RM-04-018 (This RFA has been reissued, see RFA-RM-06-007)
(see addendum NOT-RM-04-013)
EXPIRATION DATE: July 27, 2004
Department of Health and Human Services (DHHS)
PARTICIPATING ORGANIZATION:
National Institutes of Health (NIH)
(http://www.nih.gov)
This RFA is developed as an NIH roadmap initiative
(http://nihroadmap.nih.gov). All NIH Institutes and Centers participate
in roadmap initiatives. The RFA will be administered by the National Eye
Institute (NEI) on behalf of the NIH.
CATALOG OF FEDERAL DOMESTIC ASSISTANCE NUMBER(S): 93.867
APPLICATION RECEIPT DATE: July 26, 2004
THIS RFA CONTAINS THE FOLLOWING INFORMATION
o Purpose of this RFA
o Part 1 Nanomedicine Initiative Description and Research Objectives
o Part 2 Solicitation of the Concept Development Memo
o Mechanism of Support
o Funds Available
o Eligible Institutions
o Individuals Eligible to Become Principal Investigators
o Special Requirements
o Where to Send Inquiries
o Submitting an Application
o Supplementary Instructions
o Peer Review Process
o Review Criteria
o Receipt and Review Schedule
o Award Criteria
o Required Federal Citations
PURPOSE OF THIS RFA
This RFA has two purposes:
o Part 1 describes a new initiative to support a network of Nanomedicine
Development Centers. This part of the RFA includes a description of an
emerging NIH vision of Nanomedicine and the scientific basis driving this
initiative.
o Part 2 presents a solicitation of applications, or more aptly, white
papers, for applicants to request support for planning the Nanomedicine
Development Centers.
o PART 1 NANOMEDICINE INITIATIVE DESCRIPTION AND RESEARCH OBJECTIVES
Nanomedicine, an offshoot of nanotechnology, is a new term whose definition
is evolving. In the present context, it refers to highly specific medical
intervention at the molecular scale for curing disease or repairing tissue.
To stimulate work in this field, the NIH will support a major research effort
to obtain the fundamental knowledge required to make nanomedicine a reality.
It is at this size scale about 100 nm or less - that biological molecules
form the basis of systems that provide structure, control, signaling,
homeostasis, and motility in cells. There have been many scientific and
technological advances in both the physical and biological sciences over the
past several years that make nanomedicine research particularly attractive at
this time. For example, new tools are being developed that permit imaging of
structure at this scale, high speed measurement of the dynamic behavior of
molecular assemblies, and measurement of forces at the molecular scale. These
advances are complemented, on the biological side, by our knowledge of the
human genome and a greater understanding of the molecular pathology of some
diseases. The future of nanomedicine shows promise for providing us with
better control of intracellular machinery, leading to better diagnostic tools
and more specific treatments of disease with fewer side effects.
The NIH Nanomedicine Vision
A goal of this initiative is to characterize quantitatively the molecular
scale components or nanomachinery of the cell and to precisely control and
manipulate these molecules and supramolecular assemblies in living cells to
improve human health. There are several other research efforts across the NIH
in nanotechnology (http://www.becon.nih.gov/nano.htm). This Nanomedicine
Initiative is distinguished from the others by its long-term focus on
characterizing cellular processes and nanomachinery and their interactions at
a level of precision that has not been achieved to date. This Initiative will
exploit and build upon other research in nanotechnology, and apply it to
studies of molecular systems in living cells which contain a multitude of
nanoscale structures, such as membrane transporters; processes, such as self-
assembly of protein-nucleic acid complexes; and nanomachines, such as
molecular motors. Well controlled manipulation of these and other
intracellular processes and structures has not yet been achieved. As a first
step, this initiative will define what is needed to precisely control
cellular events at the molecular level including data collection, concept and
model development, and creation of the physical tools for manipulating the
processes and components in living cells. We anticipate that this knowledge
will provide the essential scientific basis required to repair or replace
damaged or diseased cellular systems.
Another important aspect of this initiative is the recognition that the
precise control required to manipulate cellular components will require the
understanding and use of engineering principles. To this end, the approach
will be informed by the design principles gleaned from the molecular
processes and structures found in living cells. In other words, biological
tissues have evolved elegant, intricate pathways, molecular structures, and
"devices" at the nanoscale. The long-term goal is to exploit these designs to
build new nanoscale devices for biomedical use.
At present, there are gaps in our knowledge about most of the physical
characteristics of cellular components such as their exact quantities and
variations, location, timescales, interactions, affinities, force generation,
flexibility and internal motion. Progress, using analytical models of
molecular interactions already in hand, is stymied by this lack of
information. More comprehensive models describing cellular structures and
associations will be developed by using the knowledge gained from such
precise quantitative physical measurements. To do so, new physical methods,
instruments, and tools must be developed. In addition, computational tools
for data collection, storage, analysis and dissemination must be refined.
In examining the long-term horizon, we expect that the next level of
investigation will identify and define the design principles and operational
parameters of naturally occurring nanostructures and complexes in cells. This
knowledge will lead us to develop strategies and fabrication methods to build
nanostructures, assemblies, and systems that ultimately will lead to specific
control of various individual cellular components, from the smallest
molecules to the largest organelles, in order to treat disease or repair
damage.
If we are to achieve improved health by employing new nanoscale materials,
then this initiative bears the responsibility to investigate interactions
between the physical materials and devices that we develop and biological
tissues. Most existing nanomaterials (e.g., carbon nanotubes and quantum
dots) were not designed for biocompatibility or biodegradability. One of our
goals is to design particles, materials, and devices that can be used in
vivo.
What do we need to learn in order to engineer molecular-sized components?
What types of measurements are lacking but, if made, could propel this effort
forward? The following specific examples are presented only to illustrate
what we mean by physical, quantitative measurements that may be required to
fill gaps in our knowledge. We are not suggesting these as topics of
particular interest to this initiative or as areas that are any more or less
in need than others, but as examples to convey the ideas presented above.
Protein-Protein Interactions. Knowledge of protein interactions is crucial
for understanding the pathways and networks operating within and between
cells. Collection of protein-protein interaction information on a genome-wide
basis is now possible. However, most of the approaches available today fall
short of gathering the needed information. Yeast two-hybrid measurements, for
example, remove the protein-coding DNA sequences from the cells of origin and
place them in an artificial environment. In doing so, subtleties of the
actual intracellular behavior are lost as a consequence of this experimental
manipulation. The results are also not quantitative, for instance, with
respect to binding constants. The next generation of tools will need to
enable both qualitative and quantitative studies on the precise protein
interactions in situ.
Intracellular Transport. The transport systems present in eukaryotic cells
organize and move organelles within the cytoplasm, orchestrate and implement
the distribution of replicated chromosomes to daughter cells, and are the
basic machinery of cellular migration. Years of innovative research have
generated detailed knowledge of the cellular organization and control of
these dynamic systems. Mathematical models of their operation have been
developed, but many key parameters, such as, rates of polymerization,
nucleation, capping, or dissociation, must be estimated because they cannot
be measured directly. Indeed, measurements central to the functions of these
transport systems, such as stresses on the fibers, forces generated by
assembly of the fibers or by interactions of fibers with the motors or other
cellular structures, and force and dynamics of adhesion to substrates
currently cannot be measured in vivo.
Biomolecular Dynamics. Often, measurements of molecular processes on a
biologically relevant timescale are inadequate. For example, studies of
second messenger signaling require harvesting tens of thousands of cells to
measure significant changes of intracellular concentrations of relevant
molecules. The methods require substantial time, at least on the order of
seconds, before the first data points are measured. Is 10 seconds a rapid
enough measurement? 5 seconds? Are studies with techniques that require such
large quantities of material feasible or necessary for precision studies of
nanoscale events? Is the information from these types of studies adequate to
lead to the precision required for more refined, quantitative models?
Clearly, a very different set of tools is needed to probe intracellular
molecular events on the biologically-relevant timescales of milliseconds or
even microseconds.
These are just a few examples that typify the shortcomings in available
knowledge and technology. A primary goal of the Nanomedicine Initiative is to
stimulate development of radically new technologies that might provide novel
strategies and new insights for cell biological studies of intracellular
molecular interactions.
Formulating the Program for a Network of Nanomedicine Development Centers
Based on discussions with hundreds of scientists early in the planning for
the NIH Roadmap (Zerhouni, E., 2003, Science 302:63-72), the following
concepts have been developed for the Nanomedicine Development Centers
program. While it is anticipated that the final program will have many of
the features outlined here, the NIH invites the research community, through
the processes initiated in this RFA, to help to formulate this program.
Initially, work at the Centers will determine what additional measurements
and analytical and computational tools are needed to understand biological
system design at the molecular level. Next, the Centers will develop, refine,
and apply them to biological systems. This, in turn, will lead to using the
knowledge to engineer molecular structures, assemblies, and organelles for
treating diseased or damaged cells and tissues. We anticipate that reaching
all of these goals may require ten years or more.
Each of the Nanomedicine Development Centers will be formed around a specific
theme that will serve as a model on which to focus studies of broader
relevance. For example, a Center may choose a model molecular system or
pathway, such as a particular signaling pathway, a system of molecular
motors, a proteasomal degradation pathway, an energy transduction system, or
the transport of materials across membranes. Alternatively, a Center may
choose a cell type or disease as a model. Regardless of the specific theme,
the focus will be on the biological system and its relevance to health, not
on the technological approach, per se, since several technologies will most
likely be required to acquire the range of physical data types needed to
solve the biomedical problem. Nonetheless, the expectation is that the level
of technology development in the Centers will be high.
Additionally, each center will develop new tools as well as refine existing
ones, evaluate materials on which the tools will be based, generate tools
that can be used at large scale and high throughput, and develop novel
algorithms and modular systems for analysis and data handling that can be
merged with tools developed by other groups.
Another emphasis of this program is to develop new tools and knowledge that
can be generalized and therefore transcend any individual model pathway,
molecular assembly, cell type, or disease. Although work may begin with well
characterized models, greater efforts should be devoted to developing tools
whose potential for application is broader than the individual model system
or class of problem (e.g., cytoskeleton vs. signaling pathway vs. ion
channels vs. machinery for replication, transcription or translation).
Optimal measurement tools would be sufficiently powerful and generic that
they would not need to be re-created for each molecule (e.g., today we must
produce a GFP reporter construct for every gene and gene variant we wish to
study, or several constructs to conduct FRET studies of molecular
rearrangements). Given this approach, it will be essential for the
Nanomedicine Centers to collaborate on setting priorities and resource
allocation with other Nanomedicine Centers, in order to maximize the
resources and capabilities of the Centers. That is, each Center would not be
expected to be comprehensive but would operate as part of a network so that
new capabilities are generated efficiently and without redundancy.
These Centers will require collaboration by scientists from disciplines that
may not typically interact with each other. For example, Centers might be
populated with cell biologists, mathematicians, biochemists, engineers,
molecular biologists, statisticians, etc. A key to progress in nanomedicine
is the development of multi- and interdisciplinary teams of scientists who
together will define the properties, knowledge, and concepts required by this
initiative.
Implementing this Initiative for Developing a Network of Nanomedicine Centers
This Centers program will be developed and implemented in a different fashion
from standard NIH procedures. The scientific scope and the administrative
structure required for the Nanomedicine Development Centers are currently
only partially defined. The NIH Nanomedicine Roadmap Implementation team has
devised a novel plan to work with the scientific community to develop the
scientific and organizational ideas that will lead to a solicitation for
applications to generate these centers. Our plan will be distinguished by a
high level of interaction of potential applicants with each other and with
NIH staff prior to announcing the final solicitation. This process was
designed to stimulate new collaborations that will result in more effective
Centers. We expect that this high degree of interaction will lead to Centers
that operate as a network, with each Center working on a unique set of
problems but cooperating and sharing information with the others. Once the
Centers are funded, the NIH will continue to facilitate interaction and
collaboration among Centers with periodic meetings of key Center scientific
representatives.
A three-step process for applicants has been developed. APPLICANTS MUST
PARTICIPATE IN EACH STEP OF THE PROCESS TO BE ELIGIBLE TO APPLY FOR THE
CENTER GRANT IN 2005.
Step 1: Concept Development Memo (CDM) - the short white paper
The CDM will broadly outline the applicant's vision for the content and
structure for a nanomedicine center, as well as how planning funds would be
used to further develop this vision. Successful applicants will receive a
Concept Development Award (CDA) for developing a more extensive plan for a
Nanomedicine Center. The specific requirements for preparing the white
paper are outlined in PART 2 of this RFA (see below).
Step 2: Concept Development Plans (CDP) the long white paper
The product of the Concept Development Award is the CDP. The best features
from the submitted CDPs will be incorporated into the final solicitation for
the Nanomedicine Development Centers.
Step 3: Nanomedicine Development Center Application
Only applicant teams who have submitted both the CDM and CDP will be eligible
to apply for funding for a Nanomedicine Development Center in 2005.
The NIH Roadmap has set aside $6 million annually for Nanomedicine
Development Centers beginning in 2005. It is anticipated that three or four
awards for up to five years, will be made. Pending availability of
additional funds in 2006, the initial Centers may be expanded, or additional
awards will be made, or both. If additional awards are to be made, this
second solicitation would be open to the entire research community.
o PART 2 SOLICITATION OF THE CONCEPT DEVELOPMENT MEMO (CDM)
The CDM is a brief white paper that outlines the applicant’s vision for a
Nanomedicine Development Center and the set of problems the center might try
to solve. This vision should begin with the concepts described in this RFA,
and develop them further based upon the applicant’s understanding of the
science, the technology, and the medical needs. The applicant should also
propose a structure for the proposed center and include a budget and
justification to support activities necessary to prepare a Concept
Development Plan (CDP, see below). Concept Development Awards (CDA) will be
made by September 30, 2004, and the deadline for CDPs will be February 15,
2005. Therefore, in their CDM, applicants should propose a budget that can
be used effectively during this time period to gather key investigators for
planning meetings, to organize small workshops with members of other
scientific, clinical or engineering communities, or organize any other
planning activities that will facilitate the assembly of teams and the
production of a CDP. The award notice for the CDA will contain an explicit
term, requiring submission of a CDP to the NIH by February 15, 2005.
Applicants submitting a CDM for obtaining a Concept Development Award need to
understand the next steps in this process, because the CDM and CDA lead
directly to submission of the Concept Development Plan (CDP). Therefore, even
though this RFA only solicits the CDM, information about the CDP and
subsequent steps is presented here.
The Concept Development Plan (CDP) will be a more extensive, substantive,
white paper to (1) describe a vision for the proposed NIH Nanomedicine
Development Center, (2) describe the specific scientific and technical
approaches that the applicant team would propose in the subsequent Center
application, and (3) propose a structure for the overall NIH Nanomedicine
program, including how each Center, and the network of Centers, should be
structured and should operate. The notion that these Centers will operate as
a network is driven not only by the high value of collaborative interactions
but also by the benefits derived from sharing essential, expensive resources,
and avoiding duplication of efforts.
The vision for this Nanomedicine Initiative, expressed in this RFA, is
intentionally ambitious. Because this vision may evolve, the scientific
goals and structural ideas of how these Centers will operate may also change.
Thus, the CDP components requested in the previous paragraph should be
written to explicitly address this ambitious vision but in a critical,
rigorous fashion that might also include refining the vision and ideas
expressed here.
The CDP will include a 2 to 3 page public abstract that will be shared with
all participants in a meeting to be held at the NIH in approximately March
2005, to which all authors of substantive CDPs will be invited. The CDP will
also include 15-20 pages that will be held in confidence and used, by NIH
staff and a group of scientific consultants, in combination with information
exchanged at the March 2005 meeting, as a basis for the formal solicitation
for the Nanomedicine Development Centers. Further instructions for preparing
the CDP will be provided to CDA awardees.
In summary, the timetable for awarding the first group of Nanomedicine
Development Centers is as follows:
May 4, 2004 Public meeting to describe this RFA and the overall
Nanomedicine Initiative
July 26, 2004 Receipt of Concept Development Memos (step 1)
September 30, 2004 Funding of Concept Development Awards
February 15, 2005 Receipt of Concept Development Plans (step 2)
March 2005 Meeting of submitters of Concept Development Plans
April 2005 Publication of solicitation for Nanomedicine Development
Centers
July 12, 2005 Receipt of applications for Nanomedicine Development
Centers (step 3)
September 2005 Funding of Nanomedicine Development Centers
MECHANISM OF SUPPORT
This RFA will use a Flexible Research Authority PN1, Nanomedicine Concept
Development Award mechanism. As an applicant you will be solely responsible
for planning, directing, and executing the proposed project. This RFA is a
one-time solicitation. The anticipated award date is September 30, 2004.
FUNDS AVAILABLE
The NIH intends to commit approximately $1.5 million in FY 2004 to fund
approximately 20 new awards in response to this RFA. An applicant may request
a project period of up to 6 months and a budget for direct costs of up to
$50,000 (plus associated F&A). Although the financial plans of the NIH
provide support for this program, awards pursuant to this RFA are contingent
upon the availability of funds and the receipt of a sufficient number of
meritorious applications (CDMs). This initiative may be repeated in future
years depending on the success of the program and the availability of funds.
ELIGIBLE INSTITUTIONS
You may submit (an) application(s) if your institution has any of the
following characteristics:
o For-profit or non-profit organizations
o Public or private institutions, such as universities, colleges,
hospitals, and laboratories
o Units of State and local governments
o Eligible agencies of the Federal government
o Foreign institutions are not eligible to apply, but may collaborate
with U.S. institutions and may receive funding.
INDIVIDUALS ELIGIBLE TO BECOME PRINCIPAL INVESTIGATORS
Any individual with the skills, knowledge, and resources necessary to carry
out the proposed research is invited to work with their institution to
develop an application (CDM) for support. Individuals from underrepresented
racial and ethnic groups as well as individuals with disabilities are always
encouraged to apply for NIH programs.
SPECIAL REQUIREMENTS
The CDM is the first of three steps for applicants. In order to be eligible
to submit an application for a Nanomedicine Development Center in July 2005,
applicants must have submitted a Concept Development Memo, must have received
a Concept Development Award, and must have submitted a Concept Development
Plan.
The principal investigator or any other co-investigators listed in the CDM
may be the lead author of the CDP, and the lead author or any co-investigator
listed in the CDP may be designated as the principal investigator of the
Center application. Thus, the PI and/or applicant institution may change but
must meet all eligibility requirements. However, we expect that each CDA can
lead to only one CDP, and each CDP can only lead to one Nanomedicine Center
application.
Submission of a Concept Development Plan (CDP) by February 15, 2005, will be
an explicit requirement of the Notice of Award for all Concept Development
Awards.
WHERE TO SEND INQUIRIES
We encourage inquiries concerning this RFA and welcome the opportunity to
answer questions from potential applicants. Inquiries may fall into two
areas: scientific/research/peer review or financial/grants management
issues:
o Direct your questions about scientific/research/review issues to:
Richard S. Fisher, Ph.D.
Division of Extramural Research
National Eye Institute
5635 Fishers Lane, Room 1300
Bethesda, MD 20892-9300
Telephone: (301) 451-2020
Email: [email protected]
o Direct your questions about financial/grants management matters to:
Mr. William Darby
Chief, Grants Management Branch
Division of Extramural Research
National Eye Institute
5635 Fishers Lane, Room 1300
Bethesda, MD 20892-9300
Telephone: (301) 451-2020
Email: [email protected]
SUBMITTING AN APPLICATION
Applications (CDMs) must be prepared using only the specified pages from PHS
398 research grant application instructions and forms (rev. 5/2001; see
below, SUPPLEMENTARY INSTRUCTIONS). Applications must have a Dun and
Bradstreet (D&B) Data Universal Numbering System (DUNS) number as the
Universal Identifier when applying for Federal grants or cooperative
agreements. The DUNS number can be obtained by calling (866) 705-5711 or
through the web site at http://www.dunandbradstreet.com/. The DUNS number
should be entered on line 11 of the face page of the PHS 398 form. The PHS
398 document is available at
http://grants.nih.gov/grants/funding/phs398/phs398.html in an interactive
format. For further assistance contact GrantsInfo, Telephone (301) 710-0267,
Email: [email protected].
SUPPLEMENTARY INSTRUCTIONS
The Concept Development Memo (CDM) consists of two sections:
o Use only the following PHS 398 pages: Face Page (Form Page 1);
Description, Performance Sites, and Key Personnel page (Form Page 2);
Detailed Budget for Initial Budget Period (Form Page 4) including
justification; Biographical Sketches for the P.I. and Key Personnel; and
Checklist Form Page (include as the last page of the application).
o A white paper, in PHS 398 Continuation Page format using standard font,
spacing and margin rules. The white paper should be structured as the
applicant finds most effective. The white paper may not exceed five pages
and must be self-contained including any figures. No appendix material or
website links for additional information are acceptable. The CDM must
include:
- a broad outline of the applicant’s vision for a Nanomedicine Development
Center, with emphasis on the set of problems the center might try to solve,
and a preview of the approaches that might be used. This vision should
explicitly address the concepts described in this RFA and should develop them
further based upon the applicant’s understanding of the scientific,
technological and medical needs. Applicants are encouraged to think more
broadly than their current research program and begin developing
collaborations that would be further cultivated if the CDM results in an
award (CDA). The characteristics of the proposed team, such as expertise and
other required broad capabilities, should be described even if all of the key
individuals have not yet been identified. It would be advantageous if some
of the potential collaborators contribute to the development of the CDM.
- a plan for using the Concept Development Award to produce the Concept
Development Plan (described above) including a justified budget. The budget
may include funds for travel, workshops, and other activities required to
facilitate planning for submission of a Concept Development Plan. Up to
$1000 each for the P.I. and up to two co-investigators, to participate in the
March 2005 meeting at NIH, may also be included.
USING THE RFA LABEL: The RFA label available in the PHS 398 (rev. 5/2001)
application form must be affixed to the bottom of the face page of the
application. Type the RFA number on the label. Failure to use this label
could result in delayed processing of the application such that it may not
reach the review committee in time for review. In addition, the RFA title
and number must be typed on line 2 of the face page of the application form
and the YES box must be marked. The RFA label is also available at:
http://grants.nih.gov/grants/funding/phs398/labels.pdf.
SENDING AN APPLICATION TO THE NIH: Submit a signed, typewritten original of
the application (CDM), including the Checklist, and three signed,
photocopies, in one package to:
Center for Scientific Review
National Institutes of Health
6701 Rockledge Drive, Room 1040, MSC 7710
Bethesda, MD 20892-7710
Bethesda, MD 20817 (for express/courier service)
At the time of submission, two additional copies of the application must be
sent to:
Richard S. Fisher, Ph.D.
Division of Extramural Research
National Eye Institute
5635 Fishers Lane, Room 1300
Bethesda, MD 20892-9300
Email: [email protected]
APPLICATION PROCESSING: Applications must be received on or before the
application receipt date listed in the heading of this RFA. If an
application is received after that date, it will be returned to the applicant
without review.
REVIEW PROCESS
Upon receipt, applications will be reviewed for completeness and
responsiveness by NIH staff. Incomplete applications will not be reviewed.
If the application is not responsive to the RFA, it will be returned to the
applicant without review.
Applications that are complete and responsive to the RFA will be evaluated by
a Nanomedicine Evaluation Panel comprised of the Nanomedicine Roadmap
Implementation Working Group members and outside scientific review
consultants.
Applications will be reviewed and ranked in accordance with the review
criteria stated below. Applicants will receive a brief written summary of the
outcome of the review.
REVIEW CRITERIA
The following topics will be evaluated in the merit review of the CDM. The
Panel will weight the topics as appropriate for each application.
1. Merit of proposal for the applicant’s vision of a Nanomedicine Development
Center. The relevance of the proposed Center to the Nanomedicine Roadmap
Initiative will be evaluated. The evaluation of the proposal may include but
is not limited to:
o Justification for the model system(s) chosen
o Toolbox to be applied and developed
o Clarity of analysis of the shortcomings of current capabilities and
impediments to be overcome
o Approach to generalizing results/solutions
o Anticipated design principles to be learned from the model system
o Analysis of the need for collaborative areas and interdisciplinary
interactions
o Approach to efficiently integrating with ongoing efforts and
existing/emerging resources
o Qualifications of the investigative team
2. Merit of validity and creativity for using requested planning funds to
facilitate the planning and writing of the Concept Development Plan (CDP).
The appropriateness of the proposed budget for planning activities will also
be evaluated but will not be incorporated into the CDM ranking.
RECEIPT AND REVIEW SCHEDULE
Application Receipt Date: July 26, 2004
Scientific Merit Review Date: August 2004
Earliest Anticipated Start Date: September 30, 2004
Receipt of CDP: February 15, 2005
AWARD CRITERIA
Award criteria that will be used to make award decisions include:
o Scientific merit (as determined by review)
o Availability of funds
o Programmatic priorities.
REQUIRED FEDERAL CITATIONS
AUTHORITY AND REGULATIONS: AUTHORITY AND REGULATIONS: This program is
described in the Catalog of Federal Domestic Assistance at
http://www.cfda.gov/ and is not subject to the intergovernmental review
requirements of Executive Order 12372 or Health Systems Agency review.
Awards are made under the authorization of Sections 301 and 405 of the Public
Health Service Act as amended (42 USC 241 and 284), FY 2004 Consolidated
Appropriations Resolution P.L. 108-199, Sections 221, (a) and (b). All
awards are subject to the terms and conditions, cost principles, and other
considerations described in the NIH Grants Policy Statement. The NIH Grants
Policy Statement can be found at
http://grants.nih.gov/grants/policy/policy.htm.
The PHS strongly encourages all grant recipients to provide a smoke-free
workplace and discourage the use of all tobacco products. In addition,
Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in
certain facilities (or in some cases, any portion of a facility) in which
regular or routine education, library, day care, health care, or early
childhood development services are provided to children. This is consistent
with the PHS mission to protect and advance the physical and mental health of
the American people.
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
|
| ||||||
|
|
|
Department of Health and Human Services (HHS) |
|
|||
|
NIH... Turning Discovery Into Health® |
||||||